Nephrology

List all Categories



CKD and BP Treatment

In patients with chronic kidney disease (CKD), which one of the following statements about the impact of the treatment of hypertension and cardiovascular risk reduction is false?

  • The benefit is similar to that seen in non-CKD patients.
  • The relative treatment effect is attenuated among those with coexisting diabetes.
  • The class specific benefits of antihypertensive agents mirror those observed in the broader population.
  • The benefit is greatest in early CKD stages.
Volume 41.5 - Question 19

Levodopa for Stroke Rehab

Among patients receiving inpatient rehabilitation for acute stroke, levodopa added to standardized rehabilitation significantly improves function at 3 months compared with placebo plus standardized rehabilitation.

  • True
  • False
Volume 41.4 - Question 14

Biomarkers in Traumatic Brain Injury

A strategy using the combined measurement of the biomarkers glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) has 100% sensitivity and 100% negative predictive value for ruling out intracranial injury in patients with mild traumatic brain injury.

  • True
  • False
Volume 41.1 - Question 18

Renal Failure Among Canadian Immigrants

Immigrants to Canada are more likely to develop incident adverse kidney outcomes compared to non-immigrants.

  • True
  • False
Volume 40.6 - Question 32

Anticoagulation in Dialysis Patients with Atrial Fibrillation

Which one of the following statements regarding the use of Factor Xa inhibitors, as compared to vitamin K antagonists, in atrial fibrillation patients on dialysis is false?

  • There is a reduced risk of major bleeding.
  • There is no difference in risk of stroke and systemic embolism.
  • There is no difference in risk of acute coronary syndrome.
  • There is increased mortality.
Volume 40.5 - Question 25

Migraine Headache Prophylaxis

Candesartan is effective for prevention of episodic and chronic migraines.

  • True
  • False
Volume 40.5 - Question 21

SGLT2s in SLE and Type 2 Diabetes

The use of Sodium Glucose cotransporter-2 inhibitors in patients with Systemic Lupus Erythematosus and Type 2 Diabetes is associated with reduction in the risk of Lupus nephritis.

  • True
  • False
Volume 40.1 - Question 25

Pediatric UTI

A 5-day treatment of acute febrile UTIs in children with oral amoxicillin-clavulanic acid was non-inferior to a 10-day treatment.

  • True
  • False
Volume 39.6 - Question 14

Chronic Kidney Disease and Preventing Hospitalization

In patients with chronic kidney disease, type 2 diabetes, and hypertension (the kidney-dysfunction triad) the use of an EHR-based algorithm and practice facilitators embedded in primary care to assist providers in delivering guideline-based interventions reduces hospitalization rate at 1 year. 

  • True
  • False
Volume 39.5 - Question 3

Empagliflozin and Chronic Kidney Disease

In patients with chronic kidney disease empagliflozin reduces the risk of kidney disease progression.

  • True
  • False
Volume 39.3 - Question 39

Back to Previous Page